Dermal Periostin: A New Player in Itch of Prurigo Nodularis

Hashimoto, Takashi; Nattkemper, Leigh; Kim, Hei Sung; Kursewicz, Christina; Fowler, Emilie; Shah, Serena; Nanda, Sonali; Fayne, Rachel; Romanelli, Paolo; Yosipovitch, Gil

doi:10.2340/00015555-3702

Cited by 28 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recently reported an increased amount of dermal IL‐31 (+) cells, IL‐31Rα (+) cells and epidermal IL‐31Rα expression in lesional PN skin compared to healthy controls that were significantly correlated with itch intensity 21 . Moreover, we found that dermal deposition of periostin is increased in PN lesions compared to healthy controls and is significantly associated with both itch intensity and the amount of dermal IL‐31Ra (+) cells 22 . Altogether, Th2 related immune cells and cytokines likely play a prominent role in both the pathogenesis and pruritus associated with PN.…”

Section: The Role Of the Th2 Immune Response In Chronic Pruritic Cond...mentioning

confidence: 62%

“…21 Moreover, we found that dermal deposition of periostin is increased in PN lesions compared to healthy controls and is significantly associated with both itch intensity and the amount of dermal IL-31Ra (+) cells. 22 Altogether, Th2 related immune cells and cytokines likely play a prominent role in both the pathogenesis and pruritus associated with PN.…”

Section: Prurigo Nodularismentioning

confidence: 99%

See 1 more Smart Citation

The pruritogenic role of the type 2 immune response in diseases associated with chronic itch

Ingrasci

Lipman

Hawash

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

While there is a vast array of aetiologies that may lead to chronic pruritus, recent data suggests that many of these conditions share similar interactions between keratinocytes, nerves, and the immune system. Specifically, the type 2 immune response, including Th2 T Cells and their related cytokines, has been noted to play a major role in the development of pruritus in a variety of itchy conditions. To date, atopic dermatitis is the most striking example of this pathogenesis. However, the body of literature supporting its role in many other itchy conditions, including other inflammatory, bullous, as well as systemic diseases, continues to grow. In addition, new treatments targeting this type 2 immune system continue to be developed and investigated. In the current review, we present the current body of literature supporting the role of the type 2 immune response in itchy conditions beyond atopic dermatitis as well as potential therapeutic options that target this pathway for chronic itch.

show abstract

Section: The Role Of the Th2 Immune Response In Chronic Pruritic Cond...mentioning

confidence: 62%

Section: Prurigo Nodularismentioning

confidence: 99%

The pruritogenic role of the type 2 immune response in diseases associated with chronic itch

Ingrasci

Lipman

Hawash

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…A dysregulated Th2-biased immune response is central to the pathogenesis of PN, including cutaneous upregulation of IL-31, IL-4, IL-17, and IL-22 [81,82]. Both pruritogenic alarmins TSLP and periostin are highly expressed in the PN skin and might fuel the itch-scratch cycle via feed-forward amplification loop mechanisms, as discussed previously [82,83]. Increased expression of neuropeptides (substance P, calcitonin gene-related peptide), neurotrophins (nerve growth factor and tropomyosin receptor kinase A receptor) and endothelin, support the notion of a dysregulated neuro-immune-epithelial cross-talk, also explaining the neuronal and epidermal hyperplasia of PN skin [84,85].…”

Section: Prurigo Nodularismentioning

confidence: 90%

Pruritus as a Distinctive Feature of Type 2 Inflammation

et al. 2021

View full text Add to dashboard Cite

Pruritus is a common symptom of several skin diseases, both inflammatory and neoplastic. Pruritus might have a tremendous impact on patients’ quality of life and strongly interfere with sleep, social, and work activities. We review the role of type-2 inflammation and immunity in the pathogenesis of chronic pruritic conditions of the skin. Type 2 cytokines, including IL-4, IL-13, thymic stromal lymphopoietin, periostin, IL-31, IL-25, and IL-33 are released by mast cells, innate lymphoid cells 2, keratinocytes, and type 2 T lymphocytes, and are master regulators of chronic itch. These cytokines might act as direct pruritogen on primary sensory neurons (pruriceptors) or alter the sensitivity to other itch mediators Type 2 inflammation- and immunity-dominated skin diseases, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, scabies, parasitic diseases, urticaria, and Sézary syndrome are indeed conditions associated with most severe pruritus. In contrast, in other skin diseases, such as scleroderma, lupus erythematosus, hidradenitis suppurativa, and acne, type 2 inflammation is less represented, and pruritus is milder or variable. Th2 inflammation and immunity evolved to protect against parasites, and thus, the scratching response evoked by pruritus might have developed to alert about the presence and to remove parasites from the skin surface.

show abstract

“…Another itch mediator associated with the Th2 inflammatory response is extracellular matrix protein, periostin; one study analyzed PN lesions and found that periostin was upregulated in the dermis as well as significantly correlated with itch intensity in these patients. 19 Additional cytokines implicated in the PN immunologic cascade include tryptase, eosinophil cationic protein, histamine, prostaglandins, and neuropeptides. 1 , 3 , 14 , 16 Eosinophil cationic protein and neuropeptides are amongst the granules released by eosinophilic granulocytes, in addition to eosinophil derived neurotoxin, eosinophil protein X, and major basic protein.…”

Section: Introductionmentioning

confidence: 99%

Immunotargets and Therapy for Prurigo Nodularis

Labib¹,

Ju²,

Does³

et al. 2022

ITT

View full text Add to dashboard Cite

Prurigo nodularis is a chronic inflammatory skin disease consisting of severely pruritic nodules that can be very debilitating for patients. The basis of this skin condition is immunological dysregulation and neural amplification, driven by T-lymphocytes, mast cells, eosinophilic granulocytes, macrophages, and cytokines mediating itchy processes. Further complicating this already taxing diagnosis is the lack of approved treatment and consensus on management; although there are off-label treatments utilized as therapy. Immunomodulators are the cornerstone of treatment for PN, and additional novel therapies targeting key players in the immunological cascade are currently undergoing investigation. In this review, we will highlight targets of the immune cascade and explore current immunomodulating treatments as well as immunotherapies on the horizon for the management of prurigo nodularis.

show abstract

Dermal Periostin: A New Player in Itch of Prurigo Nodularis

Cited by 28 publications

References 14 publications

The pruritogenic role of the type 2 immune response in diseases associated with chronic itch

The pruritogenic role of the type 2 immune response in diseases associated with chronic itch

Pruritus as a Distinctive Feature of Type 2 Inflammation

Immunotargets and Therapy for Prurigo Nodularis

Contact Info

Product

Resources

About